Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Certara Partners With Thomson Reuters to Expand Data Access Through Its D360 Platform
October 22, 2013
Certara customers will now be able to view curated life sciences content from Thomson Reuters Cortellis™ alongside their proprietary scientific data
ST. LOUIS, MO – October 22, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that it is partnering with Thomson Reuters to provide its customers with access to Thomson Reuters Cortellis™ for Informatics life sciences content through its D360™ platform. Certara’s D360 is an integrated solution for the query, analysis and visualization of drug discovery and development data.
D360 facilitates information sharing within and between a pharma company’s silos of discovery, pre-clinical and clinical data. This comprehensive data integration approach allows researchers to evaluate all pertinent information when they need to make critical decisions. D360 also empowers researchers to query and analyze their data without support from the IT team, enabling them to answer their questions as soon as they conceive them.
“This partnership will enable our mutual customers to integrate Thomson Reuters’ authoritative content with other proprietary and public data that they have integrated via the D360 platform,” said Joseph Donahue, senior vice president at Thomson Reuters. “We are pleased to be working with Certara to drive innovative solutions that support the research efforts and workflows of our customers.”
For example, D360 will enable researchers studying a particular drug receptor to retrieve published information within the solution on all the molecules attached to that receptor. By streamlining data gathering and analysis across internal and external sources, this enhanced form of D360 is expected to expedite decision making and accelerate the drug development process.
“Integration with Cortellis allows D360 to provide data views that present curated public data alongside a company’s internal proprietary data. Partnering with Thomson Reuters is another exciting step forward in ensuring that D360 remains the most usable and cost effective application for allowing scientists to easily get the data they need to make the best possible research decisions.” said Jonathan Feldmann, vice president, scientific informatics at Certara.
Cortellis for Informatics provides real-time, evidence-based information through application programming interfaces, which includes published experimental pharmacology, pharmacokinetic and pharmacodynamic results; clinical trial protocols and outcomes; competitive intelligence; patent information; and pharma company press releases and presentations. It also permits quantitative structure-activity relationship analyses of experimental results reported in published papers and patents. This data can be combined to develop an investigational drug pipeline database, and also to track competitor activity.
About Certara
Certara is dedicated to improving human health by delivering a broad spectrum of software products and consulting services, spanning molecular discovery to clinical development, with special focus on supporting translational approaches to drug development. A leading provider of model-based drug development tools, Certara was formed by the acquisition and integration of industry leaders Tripos®, Simcyp™, and Pharsight® Corporation. Each Certara family brand focuses on a key phase within the drug discovery and development process; combined, they offer a unique set of scientific modeling, analysis, and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit www.certara.com
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minn., Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to http://www.thomsonreuters.com.
Certara Contact:
Diana O’Rourke, 314-951-3310
Director of Marketing
diana.orourke@certara.com
Media Contact: Certara
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com
Media Contact: Thomson Reuters
Jen Breen, 215.823.1791
Jennifer.breen@thomsonreuters.com